TDZD-8 (Standard)

TDZD-8 (Standard) is the analytical standard of TDZD-8. This product is intended for research and analytical applications. TDZD-8 is an inhibitor of GSK-3β, with an IC50 of 2 μM; TDZD-8 shows less potent activities against Cdk-1/cyclin B, CK-II, PKA, and PKC, with all IC50s of >100 μM.

Product Specifications

CAS Number

[327036-89-5]

UNSPSC

12352100

Target

GSK-3; Reference Standards

Related Pathways

Others; PI3K/Akt/mTOR; Stem Cell/Wnt

Field of Research

Cancer

Smiles

O=C(N1CC2=CC=CC=C2)N(C)SC1=O

Molecular Formula

C10H10N2O2S

Molecular Weight

222.26

References & Citations

[1]Martinez A, et al. First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J Med Chem. 2002 Mar 14;45 (6) :1292-9.|[2]Xie CL, et al. Inhibition of Glycogen Synthase Kinase-3β (GSK-3β) as potent therapeutic strategy to ameliorates L-dopa-induced dyskinesia in 6-OHDA parkinsonian rats. Sci Rep. 2016 Mar 21;6:23527.|[3]Sun A, et al. GSK-3β controls autophagy by modulating LKB1-AMPK pathway in prostate cancer cells. Prostate. 2016 Feb;76 (2) :172-83.